Effects of Acute Cytomegalovirus Infection on Rat Islet Allograft Survival by Smelt, M. J. et al.
  
 University of Groningen
Effects of Acute Cytomegalovirus Infection on Rat Islet Allograft Survival





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2011
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Smelt, M. J., Faas, M. M., Melgert, B. N., de Vos, P., de Haan, B., & de Haan, A. (2011). Effects of Acute
Cytomegalovirus Infection on Rat Islet Allograft Survival. Cell Transplantation, 20(8), 1271-1283.
https://doi.org/10.3727/096368910X545077
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Cell Transplantation, Vol. 20, pp. 1271–1283, 2011 0963-6897/11 $90.00 + .00
Printed in the USA. All rights reserved. DOI: http://dx.doi.org/10.3727/096368910X545077
Copyright  2011 Cognizant Comm. Corp. E-ISSN 1555-3892
www.cognizantcommunication.com
Effects of Acute Cytomegalovirus Infection on Rat Islet Allograft Survival
M. J. Smelt,* B. J. de Haan,* M. M. Faas,* B. N. Melgert,* A. de Haan,† and P. de Vos*
*Department of Pathology and Medical Biology, Division of Medical Biology, Section Immunoendocrinology,
University Medical Center Groningen and University of Groningen, Groningen, The Netherlands
†Department of Medical Microbiology, Division Molecular Virology, University Medical Center Groningen
and University of Groningen, Groningen, The Netherlands
Transplantation of pancreatic islets is a promising therapy for the treatment of type 1 diabetes mellitus.
However, long-term islet graft survival rates are still unsatisfactory low. In this study we investigated the
role of cytomegalovirus (CMV) in islet allograft failure. STZ-diabetic rats received an allogenic islet graft
in combination with either an acute CMV infection or control infection. A third group received ganciclovir
treatment in addition to the CMV infection. Graft function was assessed by measuring basal blood glucose
levels. After sacrifice, the islet grafts were retrieved for analysis of infection and leukocyte infiltration.
CMV-infected recipients demonstrated accelerated islet graft failure compared to noninfected controls. CMV
infection of the graft was only observed prior to complete graft failure. Quantification of the leukocyte
infiltration demonstrated increased CD8+ T-cell and NK cell infiltration in the CMV-infected grafts com-
pared to the controls. This suggests that CMV infection accelerates immune-mediated graft destruction.
Antiviral ganciclovir treatment did not prevent accelerated graft failure, despite effectively decreasing the
grade of infection. Our data confirm the recently published CITR data, which state that CMV is an indepen-
dent risk factor for failure of islet grafts. Also, our data demonstrate that new approaches for preventing
virus-induced islet allograft failure may be required.
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INTRODUCTION of these factors may lie at the basis of declining graft
function (21,46).
It is surprising that the role of cytomegalovirus (CMV)After more than three decades of research into the
principle applicability of clinical islet transplantation has gained only minor attention as a contributing factor
to islet graft failure. This is despite the strong correlation(3,37), a major breakthrough was achieved in 2000 by
Shapiro et al. (47), who demonstrated that insulin inde- between this viral infection and solid organ graft rejec-
tion (1,13,17,24,32,48). CMV is a widely spread, persis-pendence could be achieved by applying a glucocorti-
coid-free immunosuppressive regimen after grafting the tent infection, which develops asymptomatic in healthy,
immunocompetent individuals (16). In immunocomprom-islets into the liver of diabetic patients. This success has
led to a tremendous growth in the number of clinical ized individuals, the virus may reactivate and cause mild
to severe CMV disease. A secondary feature of the virusislet transplantations performed worldwide. In spite of
this optimism, a number of critical issues remain to be is that its reactivation is strongly associated with allo-
graft rejection. In solid organ transplantation, this risksolved. Islets from more than one donor are required to
supply patients with sufficient graft volume (46). An- on CMV-induced graft failure highly depends on the
serostatus of both donor and recipient. The highest riskother important issue is that graft function declines in
the years after transplantation, with only 20% of the pa- on accelerated graft failure is observed in seronegative
[non-CMV-carrying (R−)[ recipients receiving a grafttients remaining insulin independent 5 years after trans-
plantation (6,46). The exact causes of islet allograft fail- from a seropositive [CMV-carrying (D+)] donor (14).
This process appears to develop independent of inhibi-ure remain to be identified, but a high metabolic pressure,
recurring autoimmunity, alloimmunity, or a combination tion of viral replication by antiviral medication (24,49).
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As for islet transplantation, the role of CMV in the ways exceeded the therapeutic 150 µg/L necessary for
islet engraftment (43), but is sufficiently low to preventfailure of islet grafts was only recently recognized (6).
The 2009 CITR report pointed to donor CMV seroposi- CsA-induced islet toxicity (43).
RCMV infection develops in a similar manner astivity combined with recipient seronegativity as an inde-
pendent risk factor for graft failure after islet transplan- HCMV infection in humans (51,52). In immunocompe-
tent animals, the infection develops asymptomatic, whereastation. Before this report, studies that addressed the CMV
issue in islet transplantation mostly focused on the low in immunocompromized rats it develops in a generalized
infection, characterized by hepatitis, splenitis, and throm-CMV seroconversion rates and the absence of CMV dis-
ease after transplantation (2,8,19,20,63). This absence of bocytopenia (51,52). Since islet grafts are small in size,
the transplanted viral load is considered to be low. ToCMV transmission or de novo infection may be the re-
sult of adequate antiviral treatment given prophylactic- mimic this clinical situation, rats received a nonlethal
low-dose CMV infection of 2 × 105 plaque-forming unitsally in the peritransplant period. Only two studies ad-
dressed the role of CMV in islet graft survival. Warnock (pfu).
The endocrine graft volume of 5 µl (57) was trans-et al. (60) merely suggested the negative effect of the
virus on islet graft survival, whereas Eckhard et al. (12) planted under the kidney capsule to allow full retrieval
and histological study of the grafts after sacrificing thefound high CMV transmission rates and a trend towards
reduced graft function in CMV-positive recipients after animals. Transplantation of an endocrine volume of 5 µl
is generally accepted to study the effects of experimentalcombined islet–kidney transplantation, even when anti-
viral treatment was applied (12). Together with a high treatments on islet graft survival (11,57). Transplanta-
tion was considered successful when nonfasting blooddegree of CMV mismatches between islet donors and
recipients, especially the R−/D+ combination (20), these glucose concentrations reached levels below 10 mmol/
L. One day after transplantation, the islet graft recipientsstudies clearly point to a role of CMV in islet graft
failure. received a CMV infection (N = 10). CMV infection at
day 1 after transplantation, via intraperitoneal injection,Studies unarguably proving or excluding the deleteri-
ous effect of CMV on islet grafts and discussing its is in solid organ transplantation models generally ac-
cepted to study the effects of the virus on graft survivalmechanism of action are lacking. At this point, interpre-
tation of results from patient studies is difficult, as they (23,25,29). We chose to use this model, rather than in-
fection via the islet graft, since it allows us to controlshow limitations in respect to size and characteristics
of the experimental groups. Therefore, we decided to the timing as well as the grade of infection. MOCK-
infected, transplanted animals (N = 11) served as con-investigate the role of CMV in islet transplantation in an
acute rat infection model (i.e., a model in which CMV trols. CMV-infected and control animals were trans-
planted as pairs or two CMV-infected animals and oneis given directly after transplantation) (23,25,29). These
models are generally accepted and well controlled in control. The necessary number of standardized islet
grafts was prepared from one pool of isolated islets toterms of the provided viral load and the lack of over-
shadowing and interfering secondary infections. Further, ensure that both CMV-infected recipients and matching
controls received identical islet grafts.we aimed at identifying the mechanism by which CMV
exerts its effect. In addition, we mimicked the clinical Recipients of islet grafts were followed and moni-
tored by measuring blood glucose levels, until graft fail-situation, in which prophylactic ganciclovir treatment is
applied to prevent CMV viremia and disease. ure occurred. Graft failure was defined as two blood glu-
cose measurements exceeding 20 mmol/L. Six of the
MATERIALS AND METHODS CMV-infected animals were sacrificed at the time of
Study Design complete graft failure. At the same time, the matching
control animals were sacrificed (N = 4). Three controlStreptozotocin (STZ) diabetic Albino Oxford (AO)
rats were transplanted with an islet allograft. To study animals were followed up until complete graft failure.
Moreover, four CMV-infected and four matching con-the effects of CMV in islet graft survival we used a
model that is generally accepted in solid organ trans- trols were sacrificed at 7 days after transplantation to
gain more insight in the processes underlying islet graftplantation (4,30), rather than the clinical immunosup-
pressive protocol, which has been demonstrated to in- failure. After sacrifice, the grafts, salivary glands, and
native pancreata were retrieved for immunohistochemi-duce severe insulin resistance and β-cell toxicity in rats
(35). In our model, a 10-day low-dose cyclosporine A cal staining.
In a third experiment, the effect of antiviral treatment(CsA) immunosuppression protocol is applied, which is
generally used to prevent acute rejection after solid or- on the CMV-induced graft failure was investigated. To
this end, a group of transplanted recipients (N = 5) re-gan transplantation (4,30). This protocol induces ade-
quate immune suppression, since plasma CsA levels al- ceived the clinically applied antiviral ganciclovir treat-
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ment in addition to a CMV infection. Ganciclovir treat- been demonstrated to prevent long-term graft rejection
in 75–100% of the transplanted animals (43). Plasmament at a dose of 20 mg/kg/day has been demonstrated
to be efficacious in suppressing lethal, generalized CMV CsA levels were monitored, and exceeded the therapeu-
tic 150 µg/L in all animals during the whole course ofinfection in rats (53,54).
the experiment (43). Plasma CsA levels were deter-
Experimental Animals and Diabetes Induction mined by Liquid-Chromatography-Mass Spectometry-
Mass-Spectometry. Rats received 20 mg/kg ganciclovirSpecified pathogen-free inbred male Albino Oxford
rats (RT1u) weighing 280–300 g served as islet recipi- (Cymevene, Roche, Woerden, The Netherlands) intra-
peritoneally (IP) on a daily basis, for 10 days, startingents. Pathogen-free inbred Lewis rats (RT1l) weighing
300–320 g served as islet donors. All experimental ani- from the day of CMV infection (34).
mals were obtained from Harlan (Horst, The Nether-
RCMV Infectionlands). The animals were fed standard rat chow and
acidified water ad libitum. All animal experiments were Rats received a RCMV infection by IP injection of
2 × 105 pfu of RCMV (Maastricht strain) at day 1 afterperformed after receiving approval of the institutional
Animal Care Committee of the Groningen University transplantation. RCMV was obtained by homogeniza-
tion of salivary glands of irradiated, acutely infected AOand all animals received human care in compliance with
the Dutch Law on Experimental Animal Care. rats as described previously (5). MOCK-infected islet
allograft recipients served as controls. MOCK infectionDiabetes was induced in the recipient rats by injec-
tion of 75 mg/kg streptozotocin (Zonasar, Upjohn Co., was established by IP injection of virus-free salivary
gland homogenate at day 1 after transplantation. Virus-Kalamazoo, MI) in the tail vein. Animals received a sec-
ond injection of 90 mg/kg streptozotocin when at day free homogenate was obtained by homogenization of
salivary glands of irradiated, noninfected AO rats.10 after the first injection blood glucose levels were less
than 20 mmol/L. Only animals showing weight loss and
Chemical Determinationsblood glucose levels exceeding 20 mmol/L over a period
of 2 weeks served as islet graft recipients. The absence Nonfasting blood glucose levels were determined in
blood sampled from the tail vein once every 2 days. Theof functional β-cells in the native pancreas, defined as
less than 5% of normal controls, was always confirmed glucose concentration was determined using the Accu-
Chek Sensor system (Roche). Two blood glucose levelsafter sacrifice.
exceeding 20 mmol/L in a 2-week period was consid-
Islet Transplantation ered as reestablishment of diabetes and complete islet
graft failure.Islets were isolated from pancreata of Lewis rats as
previously described (10), separated from exocrine tis-
Immunocytochemistrysue by centrifugation over a discontinuous dextran gra-
dient (58) and further purified by handpicking. After this At sacrifice, the kidney with the islet graft and the
salivary glands were removed and snap frozen in liquidprocedure, the purity of the islet graft was close to
100%. The total islet volume obtained by the isolation nitrogen. The native pancreas was removed and fixed in
Bouins fixative for paraffin processing. The pancreasprocedure was determined by measuring the diameters
(57) of the islets in a 2% aliquot of the islet suspension. was sectioned at 5 µm and stained with aldehyde fuchsin
to determine the presence or absence of functional β-Subsequently, the total islet volume was calculated, as-
suming the islets to be perfect spheres. The graft volume cells.
The islet graft and the salivary glands were sectioned(5 µl) was expressed in microliters, as previously re-
ported by our group (15,57,62), which corresponds to at 5 µm, fixed for 10 min in ice-cold acetone, and air
dried for histological examination. Endogenous peroxi-approximately 11,000 IEQ/ kg body weight. Transplan-
tation under the kidney capsule was performed at the dase was blocked for 20 min in methanol (Merck, Darm-
stadt, Germany) containing 1% hydrogen peroxide (kid-upper pole by carefully expelling the islets from a poly-
ethylene tube introduced at the lower pole of the kidney, ney and islet graft) or in phosphate-buffered saline (PBS)
containing 0.15% hydrogen peroxide (salivary glands).immediately after isolation.
Primary antibodies were incubated for 1 h, and second-
Immunosuppression and Antiviral Treatment ary antibodies were incubated for 30 min. The whole
procedure was performed at room temperature. PrimaryRats received 5 mg/kg CsA (Sandimmune, Novartis,
Basel, Switzerland) subcutaneously on a daily basis, monoclonal antibodies used were: mAb8 (1:8) (26)
against RCMV R44-protein, OX35 (undiluted, ATCC)starting directly after transplantation. To prevent CsA
cytotoxicity on the islet grafts (43), CsA immunosup- against CD4, OX8 (undiluted, ATCC) against CD8, and
NKRP1A (1:50) (BD Pharmingen, San Jose, CA) againstpression was stopped after 10 days. This protocol has
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NKRP1A-positive NK cells. Secondary antibodies used counted. During analysis, the percentage of CD25+ and
FoxP3+ T cells was determined based on the sampleswere: horseradish peroxidase-conjugated rabbit anti-
mouse IgG1 or IgG2a (Dako, Glostrup, Denmark), and stained with the isotype controls. The isotype controls
were used to set the gate, in such a way that 99% of thebiotin-conjugated goat-anti-mouse IgG1 or IgG2a (Dako).
Peroxidase activity was demonstrated by using 3-amino- cells were negative. Then, the gate was copied to the sam-
ples stained with anti-CD25 and anti-FoxP3, and the per-9-ethyl-carbazole (Sigma), biotin labeling was demon-
strated using horse-radish peroxidase conjugated Strep- centage of positive cells was determined. Data were ana-
lyzed using Winlist 5.0 software (Verity Software House).tavidin (Dako), and subsequent 3,3-diaminobenzidine
(DAB) staining (Sigma). In all control sections, PBS
Statistical Analysiswas used instead of the primary antibody. All control
Values are expressed as median with quartiles. Statis-sections were consistently negative.
tical comparisons between the groups were performed
Measurement of Leukocyte Infiltration by the Mann-Whitney U-test. Statistical significance in
the Kaplan Meier survival curve was calculated usingMorphometry was used to quantify the infiltration of
the log rank test. Values of p < 0.05 were considered toCD4+ T cells, CD8+ T cells, and NKRP1A+ NK cells.
be statistically significant.Sections were stained as described above and analyzed
using a Leica microscope with a 20× objective lens
RESULTS(Leica, Wetzlar, Germany) and Qwin software (Qwin
Restoration of Blood Glucose Levels4.0, Leica Microsystems, Annandale, NY). The staining
Following Transplantationthreshold was set manually, based on the negative con-
trol section, and subsequently, the total staining area was After allogenic islet transplantation, complete nor-
measured using Leica Qwin software. Leukocyte influx moglycemia, defined as blood glucose levels below 10
was expressed as the stained surface area as a percentage mM, was restored in 73% (8/11) of the MOCK-infected
of the total surface area. Per section, the complete islet control recipients within 4 days after transplantation,
graft was analyzed, which generally comprised 8–10 while only 50% (5/10) of the CMV-infected animals
microscopic fields. Non-islet graft tissue, such as kidney completely restored normoglycemia within 3 days after
tissue, within the analyzed field, was excluded from transplantation. The time to reach normoglycemia was
analysis. not significantly different between the CMV-infected
and control animals. Body weights (MOCK 236.6 ±
Flow Cytometry 18.47 g vs. CMV 248.3 ± 12.6 g) and plasma CsA levels
Blood T cell subpopulations were harvested from (MOCK 1389 ± 27.97 µg/L vs. 1689 ± 302.1 µg/L)
heparinized blood, sampled from the tail vein, and in were not significantly different between the MOCK-
splenocytes harvested from the spleen after sacrifice. infected and the CMV-infected animals at day 0 and day
The blood sample (1 ml) was 1:1 diluted with PBS and 7 after transplantation, respectively. The animals that did
centrifuged (20 min, 2,500 rpm, 4°C). The erythrocytes not reach the criteria for complete normoglycaemia did
were lysed by incubation in NH4Cl for 10 min at 4°C. show a reduction of blood glucose levels, demonstrating
For four-color flow cytometry, 1 × 106 cells were re- the functionality of the transplanted islet grafts. All ani-
suspended in PBS containing 5% fetal calf serum (FCS) mals gained weight after islet transplantation and the
and 0.1% sodium azide (PBS/FCS/azide). Cells were in- general health status improved. The low-dose CMV in-
cubated with a cocktail of primary antibodies for 1 h at fection had no direct consequences for the weight devel-
room temperature in the dark. Primary antibodies used opment or the appearance of the animals.
were: PerCP-conjugated R73 (1:100) against the rat T-
Islet Allograft Survival in the Presence and Absencecell receptor (BD Pharmingen), FITC-conjugated anti-
of a CMV InfectionCD4 (BD Pharmingen), PE-conjugated anti-CD25 (BD
Pharmingen), APC-conjugated anti-FoxP3 (eBioscience, Six of the CMV-infected animals were followed up
until complete graft failure, as well as three MOCK-San Diego, CA), or corresponding isotype controls. The
intracellular staining was performed according to the infected controls. The CMV-infected animals demon-
strated significantly accelerated graft failure (p < 0.01),FoxP3 staining kit protocol (eBioscience). After stain-
ing, the cells were washed twice, resuspended in PBS/ compared to the MOCK-infected control recipients (Fig.
1A, B). Moreover, the four controls that were sacrificedFCS/azide, and analyzed by flow cytometry (FACS Cal-
ibur, Beckton Dickinson). at the same time of their respective CMV-infected part-
ner did not show signs of graft failure at the time ofDuring flow cytometry, at least 1 × 105 lymphocytes,
based on the forward and side scatter pattern, were sacrifice (e.g., blood glucose levels >20 mM). At day 13
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allografts, despite adequate levels of CsA immunosup-
pression.
CMV Infection of Islet Grafts and Salivary Glands
To gain more insight into the mechanism of CMV-
accelerated islet graft failure, we studied the CMV infec-
tion in the islet allograft tissue and the salivary glands.
To study the processes preceding graft failure, four
CMV-infected and four MOCK-infected recipients were
sacrificed 7 days after transplantation (i.e., before com-
plete graft failure).
Retrieved grafts and salivary glands were stained for
the presence of CMV-R44 protein (Fig. 2). At day 7
after transplantation, as well as at the time of graft fail-
ure, all salivary glands of the CMV-infected animals
demonstrated R44+ cells (Fig. 2A), demonstrating the es-
tablishment of a generalized CMV infection. CMV in-
fection of the islet grafts was demonstrated by the pres-
ence of R44+ cells in the functioning grafts retrieved at
day 7 after transplantation (Fig. 2C). R44+ cells were not
found in the grafts retrieved at the time of complete graft
failure (Fig. 2D). The salivary glands and grafts of non-
infected control recipients were consistently negative
(Fig. 2B, E, F).
Immune Responses in the Islet Graft
Since CMV infection has previously been associated
with increased immune activation and accelerated im-
mune-mediated solid organ graft rejection (13,24,32,
33,48,59), we studied the infiltration of the CD4+ andFigure 1. Islet graft function and survival CMV-infected CD8+ T cells in the islet grafts of CMV-infected andrecipients and MOCK-infected controls. Graft survival was
MOCK-infected control recipients. Since NK cells arefollowed up in all CMV-infected (solid line, N = 6) and
MOCK-infected (dashed line, N = 7) animals that demon- known to be important in the defense against viral infec-
strated functional islet grafts after transplantation. Graft failure tions, especially in the absence of functional T-cell re-
was determined as two consecutive blood glucose measure- sponses (41,61), the infiltration of NK cells was also
ments above 20 mmol/L. Results are presented as the percent- investigated.age of nondiabetic islet allograft recipients. Statistical signifi-
In all grafts, CD4+ and CD8+ T cells were observedcance was calculated using the Kaplan Meier log-rank test
(**p < 0.01) (A). After transplantation, blood glucose levels (Fig. 3A, B). T cells were found scattered throughout
were reduced in both CMV-infected recipients (solid line) and the graft, but in the CMV-infected and control grafts that
MOCK-infected controls (dashed line). Blood glucose levels were retrieved at day 13 after transplantation, T cellsgradually increased, demonstrating gradual islet graft failure
were also organized in dense clusters (Fig. 3A, B, de-(B). Results are depicted as the mean ± SEM.
picted by the arrows). This was not observed in the
grafts retrieved at day 7 after transplantation. Also, NK
cells were found scattered throughout the islet grafts
(Fig. 3C).after transplantation (i.e., the time of complete graft fail-
ure in the CMV-infected animals), all animals demon- Morphometric analysis demonstrated that the number
of infiltrating CD4+ T cells did not significantly changestrated sufficient, nontoxic levels of CsA immunosup-
pression (i.e., above the therapeutic levels of 150 µg/ml) over time, nor did the number of infiltrating CD4+ T
cells differ between the CMV-infected recipients and the(43). This was not significantly different between the
CMV-infected recipients and the noninfected controls controls (Fig. 3A). In the CMV-infected recipients, the
number of CD8+ T cells and NK cells infiltrating the islet(controls: 335 ± 58 µg/L vs. CMV-infected recipients
334.8 ± 48.54 µg/L). These results demonstrate that grafts increased in time and was significantly increased
compared to the MOCK-infected controls at the time ofCMV infection impairs the functional survival of islet
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Figure 2. CMV infection of islet grafts and salivary glands. Histological staining of the salivary glands showed the presence of
R44 nuclear staining in the CMV-infected recipients (arrows, 40× original magnification, day 13) (A), but not in the salivary glands
of MOCK-infected recipients (40× original magnification, day 13) (B). Histological staining of the islet allografts demonstrated
R44+ cells in the grafts retrieved at day 7 after transplantation (C), but not in the grafts retrieved at the day of complete graft failure
(e.g., day 13 after transplantation) (20× original magnification) (D). Islet graft tissue of the MOCK-infected control animals was
consistently negative (E, F) (20× original magnification). Histological panels show grafts representative for the analyzed groups.
complete graft failure (CD8 T cells, p < 0.05, NK cells, different time points after transplantation. As a measure
for immune activation, the proportion of FoxP3−p < 0.01) (Fig. 3B and C, respectively).
CD25+CD4+ effector T cells was determined. As a mea-
Systemic Immune Activation sure for immune regulation the proportion of FoxP3+
CD25+CD4+ regulatory T cells was determined (44).To investigate whether the observed differences in
immune cell infiltration were also observed systemi- Although systemic CsA immunosuppression was ap-
plied, the peripheral balance between FoxP3−CD25+cally, we determined the proportion of circulating ef-
fector cells and regulatory CD4 T cells in the blood at CD4+ effector T cells and FoxP3+CD25+CD4+ regulatory
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T cells was shifted towards immune activation rather cells, as well as an increased frequency of effector T
cells. These changes were not observed in the MOCK-than to immune regulation. In the CMV-infected recipi-
ents, the ratio between CD4 effector T cells and regula- infected recipients (data not shown).
Frequencies of effector T cells and regulatory T cellstory T cells increased from 1.86 (0.59–2.58) at 1 day
prior to transplantation to 4.00 (2.68–5.49) at day 13 in the spleens at the time of complete graft failure did
not differ between CMV-infected and MOCK-infectedafter transplantation (p < 0.05). The ratio between CD4
effector T cells and regulatory T cells did not signifi- recipients (data not shown).
cantly change in the MOCK-infected recipients [2.37
Antiviral Treatment Does Not Prolong Islet(1.64–3.22) at day −1 vs. 2.67 (2.11–6.80) at day 13].
Allograft FunctionAlthough it did not reach statistical significance, the in-
creased ratio between CD4 effector T cells and regula- Since it is thought that a generalized systemic CMV
infection is a requirement for CMV-induced effects ontory T cells in the CMV-infected recipients could be at-
tributed to both a decreased frequency of regulatory T islet grafts, we questioned whether antiviral treatment of
Figure 3. Immune cell infiltration of islet grafts. Islet grafts were stained for CD8, CD4, and NKRP1A. Both MOCK- and CMV-
infected animals demonstrated the presence of CD4+ T cells (A), CD8+ T cells (B), and NKRP1A+ NK cells (C), both at day 7 and
day 13 after transplantation. Histological panels (all 20× original magnification) show grafts representative for the analyzed groups.
Leukocyte infiltration was quantified by measuring the percentage of stained surface area within the islet allografts by morphometry.
Infiltration of CD4+ T cells was not significantly different between the analyzed time points or between CMV-infected animals and
controls (p = 0.2) (A). Grafts demonstrated somewhat increased infiltration of CD8+ T cells in CMV-infected animals (solid bars)
compared to control animals (white bars) at day 7 after transplantation and significantly increased infiltration at day 13 after
transplantation (p < 0.05) (B). Infiltration of NKRP1A+ NK cells was significantly increased in the islet grafts of CMV-infected
animals compared to control animals at day 13 after transplantation (p < 0.05) (C). Results are depicted as median and quartiles.
Statistical significance was calculated using the Mann-Whitney U-test (E). *p < 0.05.
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the CMV infection could prevent CMV-accelerated graft ical effects can be identified, which could be missed in
more latent, chronic infection models. In order to deter-failure. To this end, an additional group of islet graft
recipients was studied, which received ganciclovir treat- mine the deleterious effects of CMV infection on islet
grafts, it is necessary to use a controllable infectionment in addition to a CMV infection.
Following islet transplantation, 80% (4/5) gan- model. For the present experiments, we therefore chose
to induce the CMV infection systemically, rather thanciclovir-treated CMV-infected islet graft recipients re-
stored normoglycemia. This was a higher survival rate via the islet graft itself. It might be argued that, due to
the systemic CMV infection, the infection-induced isletcompared to the nontreated CMV-infected group, but
this did not reach statistical significance. The animals graft failure is not of any clinical relevance, since sys-
temic viremia is rarely observed after clinical islet trans-that successfully restored normoglycemia demonstrated
similar islet graft failure rates as the nontreated CMV- plantation (2,6,8,19,20,63). However, the absence of
systemic viremia after clinical islet transplantation mayinfected recipients, which was significantly accelerated
compared to the MOCK-infected controls (p < 0.05 gan- be directly attributed to the use of ganciclovir prophy-
laxis (2,6,19,20). However, when we studied the effectsciclovir-treated recipients vs. controls, CMV-infected re-
cipients vs. ganciclovir-treated recipients not significant, of ganciclovir in combination with a CMV infection, we
also found a reduction in graft survival, despite the suc-log-rank test) (Fig. 4).
After sacrifice, R44+ cells were observed in the sali- cessful suppression of systemic infection. Thus, accord-
ing to these results, systemic CMV infection is not anvary glands, but the number was low and in most ani-
mals absent, illustrating the efficacy of the treatment. absolute requirement for CMV-induced accelerated islet
graft failure. We therefore feel that our observations areR44+ cells were not observed in the retrieved islet grafts
(not shown). Systemically, ganciclovir treatment was of great clinical relevance.
Our experimental rat study demonstrated acceleratednot able to suppress CMV-induced immune activation,
since the ratio between CD4 effector T cells and regula- graft failure and enhanced immune activation and infil-
tration in the CMV-infected recipients compared to non-tory T cells increased in a similar manner as in the
CMV-infected recipients that did not receive ganciclovir infected controls. This corroborates the results presented
in the 2009 CITR report (6), which states that also hu-[from 3.50 (2.05–4.19) 1 day prior to transplantation to
5.26 (5.05–6.29) at day 13 after transplantation (p < man islet graft failure is accelerated in the presence of a
CMV infection. Furthermore, we demonstrated that gan-0.05)]. In contrast to the systemic circulation, we found
an effect of the ganciclovir treatment on the CMV-induced ciclovir treatment, which is routinely applied after clini-
cal islet transplantation (46), did not prolong the func-infiltration of leukocytes in the graft. In all ganciclovir-
treated recipients we found CD4+ and CD8+ T cells, as tional survival of islet allografts. The results from the
present study suggest that several mechanisms of graftwell as NK cells, but ganciclovir treatment decreased
the infiltration of CD8+ T cells to the levels observed in failure may be involved, which will be outlined below.
Although the infectability of islet grafts was demon-MOCK-infected controls (Fig. 4B). The infiltration of
NK cells was even less than observed in the CMV- strated by the presence of R44+ cells in the grafts re-
trieved 6–7 days prior to complete graft failure, theinfected recipients (p < 0.05) or MOCK-infected con-
trols (p < 0.05) (Fig. 4B). number of infected cells appeared to be too low to sup-
port complete graft failure based on cytolytic infectionIn conclusion, these data demonstrate that ganciclovir
treatment can prevent systemic CMV infection and di- alone. This finding suggests that CMV infection may
have direct deleterious effects, but also that other mech-rect infection of the islet graft, but it does not have an
effect on CMV-accelerated islet graft failure or systemic anisms of graft failure are involved. This is substantiated
by the observation that treatment of the infection re-immune activation.
markably reduced the number of infected cells, but
DISCUSSION could not prevent accelerated graft failure.
Many studies have demonstrated CMV-induced solidIn search of factors determining islet graft failure, we
studied the effect of CMV on the functional survival of organ graft failure via intragraft inflammation and con-
sequently accelerated graft rejection (27,36,42,55,56).islet allografts. We applied a generally accepted model
in solid organ transplantation (4,30). In the present study Our study demonstrated that this not only holds true for
solid organ grafts, but also for the failure of cellular isletwe demonstrate that this model is also very suitable for
studying the deleterious effects of acute CMV infection allografts. In solid organ transplantation, the accelerated
rejection is interpreted as the result of local CMV-inducedon cellular grafts, such as pancreatic islet grafts. An ad-
vantage of this model is that the mechanisms involved changes, such as increased MHC, adhesion molecule, or
chemokine expression, with increased immune cell infil-in CMV-induced graft failure can be studied in a short
time frame, in a controllable manner and that acute, crit- tration and subsequent allograft rejection as a conse-
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Figure 4. Ganciclovir treatment does not prolong islet graft survival. Graft survival was followed up in ganciclovir-treated CMV-
infected recipients (thin solid line, N = 5) and compared to CMV-infected (thick solid line, N = 6) and MOCK-infected (dashed
line, N = 7) animals. Graft failure was determined as two consecutive blood glucose measurements above 20 mmol/L. Results are
presented as the percentage of nondiabetic islet allograft recipients. Statistical significance was calculated using the Kaplan Meier
log-rank test. The asterix represents a statistical significant difference between ganciclovir-treated recipients and MOCK-infected
controls (p < 0.05). The survival of ganciclovir-treated recipients and nontreated CMV-infected recipients was not significantly
different (A). The number of infiltrating cells in the grafts of CMV-infected recipients (black bars), noninfected controls (white
bars), and ganciclovir-treated recipients (gray bars) was determined in the grafts retrieved at day 13 after transplantation by quantify-
ing the percentage stained surface area (B). Results are depicted as median and quartiles. Statistical significance was calculated
using the Mann-Whitney U-test (E). *p < 0.05.
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quence (27,36,42,55,56). The marked systemic immune ous CMV-induced effects in the islet graft. This was
demonstrated in the 2009 CITR report, which negativelyactivation, combined with the increased infiltration of
CD8+ T cells and NK cells in the grafts of the CMV- correlated CMV infection to islet graft failure after
transplantation. Interestingly, this effect of CMV wasinfected recipients, suggests that also in islet transplanta-
tion, CMV-enhanced immune responses against the islet found using a transplantation protocol that routinely uses
ganciclovir prophylaxis (46) to prevent systemic viremiaallograft may act in concert with direct CMV infection
of the graft to induce islet graft failure. This is in line and clinical signs of CMV infection. Treatment of clini-
cally active CMV infection with ganciclovir may revertwith our previous data demonstrating that rat pancreatic
β-cells are not only directly susceptible to RCMV infec- islet allograft dysfunction, as suggested by a case report
(8). However, subclinical CMV infection may occurtion, but that the infection also markedly enhanced the
cellular immunogenicity (50). This was characterized by even during ganciclovir treatment (18), and may be in-
terfering with islet graft function. That low-grade CMVthe increased expression of both classical and nonclassi-
cal MHC I molecules and the adhesion molecules ICAM- infection may still affect islet graft survival is corrobo-
rated by our finding that ganciclovir is ineffective in pre-1 and LFA-3 (50). In a study using HCMV and human
β-cells, similar results were found (Smelt et al., submit- venting CMV-induced islet graft failure in rats. Further-
more, also Eckhard et al. (12) demonstrated a trendted). Interestingly, in this study the upregulation of β-
cell immunogenicity was observed in a large proportion towards declining islet graft function in CMV-positive
patients. Also these patients had been treated with anti-of the cells, while only a small minority of the β-cells
demonstrated apparent CMV protein expression (Smelt viral medication and demonstrated no signs of systemic
viremia at the time of declining graft function (12).et al., submitted). This suggests that the presence of only
a few CMV-infected cells may be enough to establish Taken together, this suggests that, not only in the current
model, but also in clinical islet transplantation, subclini-enhanced local immunogenicity, leading to immune cell
activation and islet graft destruction. cal CMV infection may be an important factor contribut-
ing to islet graft loss.The presence of elevated numbers of NK cells in the
CMV-infected grafts warrants some further consider- In our experiments, all animals that demonstrated
early graft loss (i.e., CMV-infected animals) demon-ation. In the CMV-infected recipients, these NK cells
may be primarily responding to the presence of CMV in strated systemic immune activation. This activation was
characterized by increased effector T-cell versus regula-the graft (31), but the presence of NK cells in the grafts
of the noninfected controls suggests that these cells may tory T-cell ratios. This systemic immunoactivation de-
veloped independent of viral inhibition by ganciclovir,also have a role in the immune response directed against
the islet allograft. Recently, NK cells with a specific al- suggesting that systemic CMV infection and subclinical
CMV infection are equally able to skew the immuneloreactivity have been described in solid organ trans-
plantation (28,38,40). Since NK cells are inhibited by response towards activation. In what manner systemic
immune activation affects islet graft rejection remains to“self” MHC I, the lack of “self” MHC I on the islet
allografts may contribute to NK cell activation and pro- be identified. The pronounced systemic immune re-
sponse in the ganciclovir-treated animals in the absenceinflammatory and destructive NK cell effector functions.
Increased infiltration of NK cells in the CMV-infected of increased immune cell infiltration in the grafts is an
observation we cannot explain. We speculate that gan-islet grafts, as a result of graft infection and/or infection-
induced increased local immunogenicity (50), may sub- ciclovir may have direct effects on the islet graft by af-
fecting local responses. Alternatively, ganciclovir maysequently further enhance the ongoing alloimmune re-
sponse, accelerating the rejection process. have more systemical effects, which may interfere with
islet graft survival. Such effects, however, are not appar-Our finding that antiviral treatment, using ganciclovir,
does not prolong graft survival is corroborated by sev- ent from the literature, in which ganciclovir is routinely
used after clinical islet transplantation. Future researcheral studies that found similar results after solid organ
transplantation (24,49). This suggests that the immedi- efforts will focus on the effects of ganciclovir on islet
graft function and survival. At this point, we interpretate-early stages of viral infection, which are not affected
by ganciclovir (7,39), are highly contributing to acceler- our observation as a suggestion that not only the “classi-
cal” immunological rejection pathway, but other alsoated graft failure. This may also hold true in this islet
transplantation model, since Hayashi et al. (22) demon- pathways [either immunological or non-immunological
(9)] contribute to the early loss of islet grafts in thesestrated that even low-grade infection of immunocompe-
tent mice had direct effects on the β-cell insulin secre- recipients.
Clinically, the leading dogma has been that CMV in-tory capacity and inflammation of the native islets.
Moreover, after islet transplantation in humans, systemic fection was a negligible factor contributing to islet graft
failure. Only recently, with the publication of the 2009viremia may not be an absolute requirement for deleteri-
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CITR report (6), this opinion has started to change. It it would also be of interest to study the effects of a CMV
infection derived from the recipient, rather than the do-has always been assumed that islet grafts were relatively
uninfectable and contained only low amounts or no virus nor. Also, the impact of a delayed CMV infection on
graft function and survival should be established. Theparticles at all. This led to the assumption that transmis-
sion of the infection after islet transplantation, as well finding that ganciclovir did not prolong the survival of
islet allografts, despite effectively reducing the magni-as secondary CMV-induced effects on graft survival,
was rare to nonexistent. The results from the present tude of viral infection, suggests that also low-grade
CMV infection should be considered as a serious delete-study argue against this clinical reasoning, since we
demonstrated that at least several cell types within the rious factor in islet transplantation. Our data suggest that
more effective suppression of CMV infections in isletislet grafts are able to support viral infection and replica-
tion. These may also be the pancreatic β-cells, since we allograft recipients may contribute to prolongation of is-
let graft function.have previously demonstrated that pancreatic β-cells are
able to support all stages of viral replication in vitro ACKNOWLEDGMENT: This research was sponsored by the(50). The susceptibility of islet grafts for the infection is Dutch Diabetes Foundation (grant number 2004.00.024).
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